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Introduction
Gastric cancer (GC) is the fourth most common cancer and 
the second leading cause of mortality worldwide (1,2) with a 
case fatality rate of 75%. It is still one of the most important 
malignant diseases with significant geographical, ethnic and 
socioeconomic differences in distribution. Most of the GCs 
(90%) are sporadic. Familial clustering is observed only 
in 10% of cases and, among these, only 1-3% of GCs are 
considered hereditary with the inclusion of hereditary diffuse 
gastric cancer (HDGC) and the gastric adenocarcinoma 
and proximal polyposis of the stomach (GAPPS) (3-6). 
Unfortunately, most GC are diagnosed in advanced or 
metastatic stage, and palliative chemotherapy remains the 
only treatment option, while the surgical resection is the 
mainstay of treatment for patients at early-stage cancer but 
the survival rate of patients with advanced respectable GC or 
gastroesophageal junction (GEJ) cancer, remains poor.
Despite the significant improvements of modern 
technology that contributed to shed light on the molecular 
bases sustaining development, invasion and metastasis, GC 
remains a major diagnostic and therapeutic challenge. This 
is due to the wide heterogeneity of cell population with a 
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variety of genetic lesions in the same neoplastic foci, but it is 
also due to the existence of at least five cancer subtypes with 
different molecular pathogenesis and clinicopathological 
profiles, classified by the World Health Organization as: 
papillary, tubular and mucinous adenocarcinomas, mixed 
carcinomas and poorly cohesive carcinomas, with or without 
culprits of ring cells (7). More recent work by Lei et al. 
provided a further subdivision of GC according to their 
ability to respond to PI3-K inhibitors and 5-fluoracile (5-FU), 
identifying three subset of GCs described as “mesenchymal”, 
“proliferative” and “metabolic”, distinguishable for 
histological phenotypes and sustained by different patterns 
of mutated gene expression (8,9). For all these reasons the 
molecular pathogenesis of GC is complex, and this reflects 
the limited success in the treatment of this neoplasia. 
Nevertheless, in sporadic GC the more than 37% of gene 
alteration are found in the pathways of tyrosine kinase 
receptors (RTK) and are potentially drug-gable. Among 
the growth factor receptors, the EGFR family supplies 
most of the oncogenic signals through the overexpression 
of ErbB2 (15% of GCs), EGFR (40% of GCs) and through 
the expression ErbB3 documented in 62% of GC (10,11). 
FGFR2 and mesenchymal epithelial transition (MET) 
receptor amplification, phos¬phatidylinositol 3-kinase (PI3K), 
PTEN and KRAS mutations, contribute to amplify the 
signals promoting cell cycle and suppressing the apoptotic 
pathways (12,13) (Table 1).
Unlike in breast cancer, the studies in GC have produced 
conflicting findings regarding the prognostic relevance 
of ErbB2. However, most of the reports indicate the 
overexpression of ErbB2 and any of the ErbB receptors, as 
variably associated to aggressive phenotype and poor survival 
of gastric adenocarcinomas. In particular, while EGFR and 
ErbB2 overexpression can valuably predict poor outcomes 
in GC patients, high levels of ErbB3 that are commonly 
detected in advanced GC, have been associated with tumor 
resistance to EGFR- and ErbB2-targeted agents (16). 
Yet, despite any dispute over the prognostic properties 
of overexpressed ErbB2 in GC, there is more consensus 
regarding the importance of this receptor as a therapeutic 
target, fact that justifies the continue effort to develop 
and test novel biological agents in pre-clinical and clinical 
settings (17-19). The usefulness of ErbB2 targeted therapy 
has been first demonstrated by the relative success of ToGA 
trial, still considered as a landmark in the treatment of 
GC. ToGA trial reported a modest although significant 
prolongation of progression-free survival (PFS) in patients 
with ErbB2-overexpressing metastatic GC or GEJ 
adenocarcinoma treated with trastuzumab, a therapeutic 
antibody anti-ErbB2, in combination with cisplatin and 
a fluoropyrimidine (either capecitabine or 5-FU), as 
compared to chemotherapy alone (20). Results indicate 
that, while the early responses to anti-receptor therapies 
can be successfully due to uncoupling the links between cell 
surface receptors and gene expression, the progression of 
the disease is characterized by the appearance of vicarious 
or overlapping pathways for tumor growth and survival that 
decrease or abrogate the efficacy of the treatment over a 
short period of time. 
Considering the increasing incidence of gastric and GEJ 
Table 1 Molecular alteration in gastric cancer
Gene Percentage Subset of proteins Mutation type Involved pathways
RTK 37% (12) EGFR family: EGFR 45.5%* (10); 
ErbB2 20%* (10); ErbB3 62% (11)
Substitution missense 100% RAS/MEK/MAPK and PI3K/Akt/
mTOR
FGFR (13) Gene amplification 10% PI3K/Akt and MAPK-ERK 
pathways
MET (14) Gene amplification 10-20%*; protein 
overexpression 40-90%*
Ras, PI3K, STAT and Notch 
PIK3CA 5% (10) Substitution missense 100% PI3K/Akt/mTOR
PTEN 20% (15) Substitution nonsense 50%; substitution 
missense 16.67%; insertion frameshift 
16.67%; deletion frameshift 50%
PI3K/Akt/mTOR
*, percentage are reported as average from literature. RTK, receptor tyrosine kinase; MAPK, mitogen-activated protein kinase; 
mTOR, mammalian target of rapamycin; PI3K, phos phatidylinositol 3-kinase; MET, mesenchymal epithelial transition receptor 
tyrosine kinase I.
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adenocarcinomas typically displaying high ErbB2 expression 
levels, there is the urgent need to elucidate responses and 
adaptive mechanisms utilized by cancer gastric cells during 
tumor progression, but more importantly it is necessary to 
determine the optimal use of anti ErbB2 targeted therapies and 
identify rational strategies to overcome the acquired resistance.
In this review we attempt to analyze the mechanisms 
sustaining the activation of alternative oncogenic pathways 
potentially responsible for the occurrence of primary 
and secondary resistance to chemotherapy or anti-ErbB2 
therapies, indicating alternative views for the identification 
of strategies to successfully target GC with suitable ErbB2-
targeted compounds.
The ErbB2 receptor in the EGFR/ErbB signaling 
network
The EGFR receptor family is made up of four distinct 
members: ErbB1 (EGFR/HER1), ErbB2 (HER2/neu), 
ErbB3 (HER3) and ErbB4 (HER4) (21). These receptors 
are evolutionary conserved and contain functional 
redundancy to ensure signaling is maintained and effective. 
They are involved in the execution of a number of 
developmental programs that requires generation of fine-
tuned signals spatially and temporally regulated by a wealth 
of ligands necessary to elicit specific cellular responses. 
The ErbB network comprises of a ligand-dependent 
aggregation of active receptors in homo- and heterodimeric 
conformation, whose dynamics are regulated in accordance 
to a hierarchical model of inter-receptor interactions. 
In principle, the mechanism of activation of the ErbB 
receptors relies on the availability in the extracellular 
environment of ligands differently able to drive the 
formation of homo- or hetero-dimers according to their 
own binding specificities. However, ErbB2 has no known 
ligands and ErbB3 can intercept growth factor ligands 
but contains much lower intrinsic kinase activity. Indeed, 
the two impaired receptors, either in their ligand-binding 
ability (ErbB2), or in the kinase activation domain (ErbB3), 
need an interdependent and mutual interaction to supply 
to their own limited abilities. Together, they trigger and 
propagate signals leading to the activation of the Ras/Raf/
mitogen-activated protein kinase (MAPK) and PI3K/Akt/
mammalian target of rapamycin (mTOR) downstream 
signaling pathways, and for this ErbB2/ErbB3 are 
considered the most potent signaling complex in terms of 
growth and transformation (22,23).
The ErbB receptors can be variably stimulated by a 
plethora of growth factor ligands encoded by more than 
20 genes (24). Seven of these ligands bind to the EGFR and 
nine to ErbB4, with HB-EGF, epiregulin and betacellulin 
shared. ErbB3 displays more selective interactions, being able 
to bind Nrg1 and Nrg2 ligands (25-28) (Figure 1A). Notably, 
the tridimensional structure of the ErbB2 extracellular 
domain (ECD) confers unique features to this receptor that, 
at high receptor density, is able to form active dimers in 
absence of ligands and of any other receptor partner. The 
ErbB receptors can be also activated by non-physiological 
stimuli (e.g., oxidative stress, UV, and γ-irradiation) or by 
other RTKs (notably MET, IGF-1R, or TRK-B). In this 
network of highly organized interactions the receptors 
contribute to specific signaling responses by recruiting 
enzymes, adaptors and scaffolds proteins through a variety 
of recognition signals that are specific for the different 
receptor types. 
In general, quality and quantity of the signaling dimers 
depend on the stoichiometry among the all ErbB receptors 
expressed and on the availability of ligands that, in virtue 
of their affinities and binding specificities, can variably 
orient the hierarchy of receptor dimer formation. Thus, 
combination of expression level variability and inter-
receptor interactions account for a wide repertoire of 
signaling options. This complexity become particularly 
evident in tumor cells, where different co-expression 
profiles of ErbB1-4 and EGF-like growth factors define 
different cancer types and subtypes, and sustain oncogenic 
programs through the activation of specific downstream 
signaling cascades (29,30).
In relative paucity of ErbB receptors on the surface of 
cancer cells, highly expressed ErbB2 tend to aggregate to 
form active dimers able to signal even in absence of ligand. 
On the other hand, the availability of significant amount of 
other ErbB receptors allows for the distribution of ErbB2 in 
hetero-dimeric conformation, able to aggregate according to 
ligand binding specificities. This modality of activation for 
the ErbB receptors implies that ErbB2 overexpression might 
be not exhaustive to define subset of aggressive tumors, but 
should also be related to the expression of ErbB3 and EGFR, 
particularly prone to dimerize with ErbB2. 
More complexity is added by the dynamic redistribution 
of active dimers containing ErbB2 during tumor progression 
per se, or in response to anti-RTK treatments, when 
cancer cells become resistant to mono-drug therapies. 
In all cases, cancer cells redefine by time quantities and 
stoichiometry of the active dimers, with significant changes 
in the quality and potency of downstream signaling events 
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promoting proliferation, migration or anti-apoptotic 
responses. Acceptance of the “dynamic hierarchical model 
for inter-receptor interaction” implies a reinterpretation 
of the overexpression of ErbB2 in cancer cells, overall 
in light of the possibility to choose different therapeutic 
molecules, kinase inhibitors and monoclonal antibodies 
(mAbs) to specifically target ErbB2 and its numerous RTKs 
dimer partners. The major challenge is to overcome the 
reprogramming of the RTK network induced by drug 
resistance, fact that can be obtained by the combinatorial 
use of drugs diversely directed to target all the dimers 
containing ErbB2.
Activation of ErbB3: a mechanism to resist?
The limited efficacy of anti-ErbB2 therapies suggests the 
presence of alternative pathways of escape for cancer cells. 
ErbB3 is now emerging as a key player in the establishment 
of malignancy cancer progression and, above all, in the 
establishment of resistance to therapies (31). Despite 
the presence of an impaired kinase domain in its intra-
cytoplasmic region, ErbB3 can be trans-phosphorylated 
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Figure 1 The ErbB receptors can form homodimers or heterodimers according to ligand availability. (A) EGF, TGF-, HB-EGF, 
amphiregulin (AR) and betacellulin bind to the EGFR leading to its homodimerization. In presence of ErbB2, EGF drives the formation 
of EGFR/ErbB2 dimer, betacellulin and HB-EGF bind to ErbB4 leading the formation of homodimers. In presence of ErbB2, 
betacellulin triggers the activation of ErbB2/ErbB4 heterodimers. The four NRG ligands (NRG1-4) bind to ErbB3 and to ErbB4. 
NRG4 and HB-EGF bind to ErbB4 dimers only. NRG1-3, betacellulin and, to a lesser extent, epiregulin drive the heterodimerization of 
ErbB2 with ErbB3 and ErbB4; (B) trastuzumab blocks the ErbB2 self-aggregation and the formation of dimers with ErbB4, favoring its 
dimerization with the other ErbB receptors, particularly with ErbB3; (C) pertuzumab blocks the dimerization of ErbB2 with the other 
receptors. Upon antibody binding, redistributed ErbB2 receptors create active dimers able to signal in presence of appropriate ligands, 
while EGFR, ErbB3 and ErbB4 can variably aggregate to supply signals to cells.
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by lateral signaling from other RTKs of the same or other 
families to promote activation of the PI3K/Akt signaling 
pathway. From mechanistic standpoint, the six tyrosine 
residues in its cytoplasmic tail when phosphorylated 
become high affinity binding sites for the regulatory 
subunit of PI3K. Recruitment of PI3K activity sustains 
metabolic pathways regulating cells proliferation, tumor 
size, and resistance to apoptosis and is required for the early 
steps that regulates cell motility and invasion of metastatic 
cells. Therefore, the high expression of ErbB3 has been 
associated with tumor progression, depth of invasion, lymph 
node metastasis, stage of GC and, more significantly, with a 
worse overall survival (OS) (16,19,32). Notably, the higher 
levels of ErbB2 and ErbB3 have been detected in stage III-
IV gastric adenocarcinoma compared to in stage I-II disease 
(22-24.0% vs. 5.8-7.7%, P<0.05) (33). 
The mechanisms involved in the feedback regulation of 
the PI3K/Akt axis at the ErbB3 receptor level are numerous 
and vary from the down-regulation of suppressive miRNA, 
to a FOXO-dependent induction of ErbB3 transcripts; from 
the RAS-dependent up-regulation of the NRG-1 ligand 
regulating the phosphorylation of ErbB3, to an inefficient 
sorting of the receptor to the degradation pathway when 
coupled with ErbB2 (34-37). All of these conditions amplify 
the ErbB3-dependent PI3K/Akt signals and lead cells to 
proliferate. 
On the other hand, many studies indicate that up-
regulation of ErbB3 may promote resistance to a number 
of inhibitors designed to antagonize the PI3K activation. 
Preliminary data sustain also the hypothesis that the 
ErbB3 receptor is involved in the activation of an early 
feedback survival loop in cells exposed to BRAF and/or 
MEK inhibitors, with a mechanism leading to enhanced 
production of NRG-1 (unpublished data).
In the last years, evidence has begun to emerge that 
ErbB3 can be activated by mutations able to confer 
transforming capabilities in vivo and in vitro. The majority 
of these mutations identified in human tumors cluster in 
the ECD region, with few of them in the kinase domain 
and in the intracellular tail of ErbB3 (38,39). Single 
amino acid substitutions found in seven hot spot positions 
in the ECD seem to confer an untethered and open 
conformation to ErbB3 that is primed for dimerization 
and activation (39). Jaiswal and colleagues found recurrent 
mutations in the ErbB3 coding region in 12% and 11% of 
gastric and colon cancers (37). Notably, these mutations 
remove the need for ErbB3 of the lateral phosphorylation 
from active kinases and therefore, it remains relevant to 
successfully target the ErbB3 mutants, to consider drugs 
that inhibit dimerization or that inhibit the kinase activity 
of the dimerization partner. 
These evidences have triggered major efforts towards the 
development of anti-ErbB3 therapies, and in particular of 
anti-ErbB3 mAbs because this receptor is devoid of strong 
intrinsic kinase activity. 
The hepatocyte growth factor (HGF)/
mesenchymal epithelial transition (MET) pathway
Recent studies have revealed that the heterogeneous 
expression of multiple RTKs throughout the tumor is a 
principal mechanism of resistance. In particular, targeted 
inhibition of a single receptor is ineffective, and this is 
apparently due to the up-regulation of other receptors 
within the same family, or to the engagement of alternative 
pathways mediated by the ligand stimulation of other 
unrelated RTKs (40,41). Among these, the signaling of the 
hepatocyte growth factor receptor (MET-HGFr) may play 
important roles.
Upon HGF stimulation, MET induces several biological 
responses including cell invasion, proliferation and 
anchorage independent growth that collectively promote 
tumor invasiveness. Those programs are sustained by 
the activation of multiple signal transduction pathways, 
including Ras, PI3K, STAT and Notch pathway, this latter 
through the transcriptional activation of Delta ligand.
From the very early studies, MET expression has been 
recognized as an important poor prognostic marker in GC 
(14,42). A total of 15% of GC patients (between 10% and 
20% in the literature) harbor c-MET gene amplification 
and 40% to 90% have protein overexpression. Both MET 
overexpres¬sion and gene alterations have been shown to 
significantly correlate with the depth of tumor invasion, 
metastatic behavior and poor prognosis, providing evidence 
for the key role of c-MET in GC and a rationale for the 
development of MET inhibitors (43-47).
Besides the canonical way of activation by natural ligands, 
Met signaling is also sustained by a bidirectional crosstalk 
with the EGFR: while EGFR inhibition reduces basal MET 
phosphorylation (48,49), MET inhibition reduces basal 
phosphorylation of EGFR, ErbB2 and ErbB3 (41,50). In 
MET overexpressing cells, MET triggers proliferation and 
anti-apoptotic signals through ErbB3 to sustain cell PI3K/
Akt survival despite EGFR inhibition (41). The mutual 
interaction existing between the EGFR family and MET is 
also supported by observations that patients with GC with 
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constitutive activation of the ErbB receptors responded 
poorly to MET inhibition, which indicates that activation of 
the MET/HGF signaling pathway is one of the mechanisms 
of resistance to EGFR/ErbB2 inhibitors (51). Interestingly 
enough, EGFR, MET and ErbB2 gene amplification are 
mutually exclusive events in GC (52).
All these evidences provide the rational for therapeutic 
actions aimed to target both the ErbB2 and MET receptors 
that, in GC subjected to single therapy against either one 
of the receptor, may link their own downstream signaling 
pathways, to become resistant.
PI3K/Akt/PTEN 
The PI3K/Akt pathway is one of the main downstream 
signaling pathways of the ErbB receptors and MET, and 
is altered in a variety of human tumor types, including 
GC. Preclinical work has demonstrated that both PI3K 
mutations and PTEN (phosphate and tensin homolog) 
inactivation cause amplification of the downstream PI3K/
Akt signals, in absence of ligand/receptor stimulation. 
The PI3KCA gene encodes for the catalytic subunit p110α 
of the PI3K heterodimeric complex. Its gene amplification 
is commonly detected in advanced gastric cancer (aGC) 
patients with frequencies close to 67%, while activating 
mutations have been described in 5% to 7.1% of GC (53,54). 
Occurrence of these mutations appears to be a late event 
in gastric carcinogenesis, because their frequency is higher 
in T4 cancers (21.4%) than in T2 cancers (6.4%) (55). It is 
consistent with the role that PIK3CA and PI3K signaling 
have in acquired resistance to upstream inhibitors, including 
trastuzumab and pertuzumab. Notably, these agents can exert 
their antitumor effects in ErbB2 overexpressing cells only in 
presence of a normal PI3K pathway.
Functional inactivation of the tumor suppressor gene 
PTEN is a dynamic process during the course of cancer 
progression and has been observed in almost 20% of the 
GC patients. Mechanisms involved in PTEN deficiency 
are mostly related to gene mutations, loss of heterozygosity 
(LOH), promoter hyper-methylation and miRNA-mediated 
regulation. PTEN deficiency can be used as an indicator to 
diagnose the pathological state of GC but most importantly, 
when evaluated in combination with ErbB2 expression, 
identifies subsets of malignant phenotypes with more 
aggressive proliferative culprits (15). Furthermore, recent 
work of Zhang and colleagues identified higher prevalence 
of PTEN deficiency in patients resistant to trastuzumab or 
lapatinib and with shorter PFS, thus qualifying PTEN as an 
important predictive marker for early resistance to ErbB2 
inhibitor treatment in GC patients (56).
Dual blockade anti-ErbB2 therapy
Trastuzumab and pertuzumab are two humanized 
recombinant antibodies currently employed to target the 
ErbB2 receptor in a variety of cancers (Figure 1B,C). These 
two mAbs have different but complementary mechanisms 
of action depending on their own ability to bind to ErbB2 
at different epitopes. Whereas trastuzumab binds to 
subdomain IV of ErbB2 to inhibit ligand-independent 
signaling, pertuzumab sterically blocks a binding pocket 
for ErbB2 dimerization with other ErbB receptors, with 
the consequence to block the ligand-activated signaling 
from EGFR/ErbB2 and, particularly, from ErbB2/ErbB3 
dimers at his source (57-59). In this case, the primary 
binding of pertuzumab to the subdomain II of the ErbB2 
ECD and to a lesser extent with the domain I blocks the 
formation of heterodimers, but does not interfere with 
the ability of ErbB2 to form homo-dimers, thus leaving 
intact their abilities to elicit oncogenic signals (59,60). 
By contrast, binding of trastuzumab to ErbB2 results in 
the inhibition of receptor homo-dimerization without 
interfering with its hetero-dimerization with ligand-
activated EGFR or ErbB3 (61,62). Beyond the inhibition 
of signal transduction through ErbB2 homo-dimers, 
trastuzumab inhibits the shedding of the ECD of ErbB2, 
which produces active truncated p95-ErbB2, suppresses 
tumor angiogenesis, inhibits DNA damage repair, while 
both trastuzumab and pertuzumab can elicit an antibody-
dependent cell-mediated cytotoxicity.
The abilities of both the antibodies have been validated 
in several clinical trials, but unfortunately not all the 
patients with tumors overexpress ErbB2 respond to 
trastuzumab, and the majority of patients who achieve an 
initial response to trastuzumab-based regimens develop 
resistance within 1 year. One possible explanation is that 
the use of one single antibody may induce by time changes 
in the kinetics of dimer formation, with ErbB2 shifting 
from homodimers to an ErbB2/ErbB3 heterodimeric 
aggregation, with consequent variation in the balance 
between MAPK and PI3K pathways. This reprogramming 
of the signaling output is the first mean for adjustment of 
cancer cells to escape from a single drug administration. 
These concepts have been carefully evaluated by Goltsov 
and colleagues that used combination of experimental and 
computational models to calculate the inhibition of pAkt 
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and pERK in cancer cells treated with pertuzumab and 
trastuzumab, alone or in combination (63). They found 
that trastuzumab alone inhibits pERK when ErbB2 is in 
homodimeric conformation (high ErbB2 and low ErbB3 
expression), but has no effects on the PI3K signaling 
on the same cells. They also proved that effectiveness 
of trastuzumab on pERK inhibition decreases in high 
density of ErbB2/ErbB3 dimers, since most of the ErbB2 
receptors signal with ErbB3. By contrast, pertuzumab is 
effective to down-regulate both pAkt and pERK in cells 
expressing high density of ErbB2/ErbB3, while it fails 
to inhibit pERK because it does not block ErbB2 homo-
dimerization (Figure 1). The combination of the two 
treatments effectively inhibits pERK activity both high 
ErbB2 and ErbB2/ErbB3 compositions, while the effects 
of either one mono-therapy depends on ErbB2/ErbB3 
dimerization kinetics that are under the strict control 
of ErbB2 and ErbB3 expression levels. In this context, 
the major role is plaid by compensatory shift in ErbB3 
activation and up-regulation, it have been observed as a 
consequence of cell reprogramming following suboptimal 
inhibition by tyrosine kinase inhibitors (TKIs), or 
resistance to single drug therapy (64).
The concept of dynamic reprogramming of the 
ErbB dimers containing ErbB2 in cancer cells subjected 
to mono-therapy is supported by in vitro and in vivo 
preclinical studies. Targeting of the ErbB2 receptor with 
the simultaneous administration of trastuzumab and 
pertuzumab caused stronger growth inhibition of SKOV3 
tumor xenograft, providing a more efficient blockade of 
the ErbB2 signaling pathway, than either antibody alone 
(65-68). Their use in combination in clinical settings has 
been successfully tested and consolidated in the Cleopatra 
study where patients with ErbB2-positive metastatic breast 
cancer treated with pertuzumab, trastuzumab and docetaxel 
significantly improved progression-free and OS compared 
with placebo, trastuzumab and docetaxel (69).
More recently, a phase IIa trial conducted to ascertain 
pharmacokinetics and safety in ErbB2-positive aGC 
patient treated with pertuzumab and trastuzumab in 
combination with capecitabine and cisplatin sustains the 
feasibility of a dual blockade anti-ErbB2 therapy with 
pertuzumab plus trastuzumab (70). Preliminary data from 
the exploratory efficacy analysis show that those patients 
treated with the combination achieved high rates of partial 
response (86% in Arm A and 55% in Arm B) or stable 
disease (SD) (14% in Arm A and 27% in Arm B) at the 
end of cycle 6. We are waiting for the result of double-
blind, placebo-controlled, randomized, multicenter, 
international, parallel arm phase III study will evaluate 
the efficacy and safety of pertuzumab in combination 
with trastuzumab, fluoropyrimidine and cisplatin as first-
line treatment in ErbB2-positive aGC or metastatic GEJ 
(Clinical Trials gov. NCT01774786).
Novel agents and promising molecules 
When the patients acquire resistance to trastuzumab, what 
to do? 
The molecular mechanisms underlying trastuzumab 
res is tance in  GC are  complex ,  and intratumoral 
heterogeneity of this tumor certainly contributes to 
resistance. In this regard, others classes of targeted drugs, 
including TKIs, such as Lapatinib and Dacomitinib, mTOR 
pathway inhibitors, such as Everolimus, have also been 
investigated and are potentially useful in clinics.
Lapatinib, an oral tyrosine kinase inhibitor of EGFR 
and ErbB2, has also been tested in ErbB2-positive GC. 
Although in preclinical studies Lapatinib was shown to 
display synergistic effects with trastuzumab in human ErbB2 
positive gastric cells, in vitro and in vivo, the randomized 
Phase III TRIO-013/Logic Trial failed to show significant 
improvement in the OS when combined with chemotherapy 
for first-line (71) or second-line treatment (72) of ErbB2-
positive aGC, indicating again, either the existence of 
alternative drug-resistant pathways of escape from ErbB2-
targeted therapies, or the induction of genetic changes 
sustaining resistance.
Dacomitinib (PF-00299804) is a second-generation 
irreversible pan-ErbB receptor tyrosine kinase inhibitor 
(selectively inhibiting EGFR, ErbB2, and ErbB4) under 
clinical development. The combination of Dacomitinib with 
chemotherapeutic agents (such as 5-FU and cisplatin) or 
targeted agents (such as trastuzumab) showed a synergistic 
effect. However, a clinical phase II study in ErbB2 positive 
patients with aGC, where Dacomitinib was given as 
monotherapy, showed a response rate of only 7.4% and an 
OS of 7.1 months.
Afatinib (Giotrif, Boehringer Ingelheim) is another oral 
irreversible pan-ErbB TKI, recently approved by FDA for 
first-line treatment of patients with metastatic NSCLC with 
EGFR exon 19 deletions or exon 21 substitution mutations. 
In GC, Afatinib has demonstrated antitumor activity in 
a ErbB2 positive xenograft mouse model and based on 
data from clinical phase II study in esophagogastric (EG) 
cancer patients, the investigators concluded that single 
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agent afatinib showed clinical efficacy in patients with 
trastuzumab refractory EG cancer. 
Crizotinib and Foretinib are c-Met inhibitors, in two small 
phase I/II studies: two patients harboring MET amplification 
were treated with crizotinib and presented tumor shrinkage 
(−30% and −16%) and experienced progression after 3.7 
and 3.5 months. Shah et al. reported 67 aGC patients who 
were treated with Foretinib irrespective of c-Met status. Best 
response was SD in 10 (23%) patients receiving intermittent 
dosing and 5 (20%) receiving daily dosing; SD duration was 
1.9-7.2 months (median 3.2 months) (73).
T-DM1 is an antibody-drug conjugate in which 
trastuzumab is conjugated to a cytotoxic compound, 
emtansine (DM1). T-DM1 combines the mode of action of 
trastuzumab with the targeted delivery of a potent cytotoxic 
(74,75). Upon binding of the trastuzumab moiety to ErbB2, 
T-DM1 is internalized into the tumor cell, releasing the 
DM1 moiety, which inhibits microtubules. A trial is now 
underway to examine the efficacy and safety of T-DM1 
compared with standard taxane therapy in patients with 
ErbB2-positive GC (NCT01641939). 
Everolimus is an oral mTOR inhibitor that demonstrated 
promising efficacy in a phase II study of pretreated aGC. 
An international double-blind phase III study compared 
Everolimus efficacy and safety with best supportive care (BSC) 
in previously treated aGC. Everolimus did not significantly 
improve OS after one or two lines of previous systemic 
chemotherapy. Its efficacy seems to be limited only to a subset 
of patients harboring PI3K and pS6 aberrations, potentially 
identifying these lesions as possible biomarkers (76,77).
Consideration and future perspectives
Despite the global downward trends in GC mortality, 
this malignancy is still one of the most highly prevalent 
leading causes of cancer-related death worldwide. This sad 
supremacy is due to multiple conditions, mostly related with 
the late time of the diagnosis, the paucity of premonitory 
symptoms and the high variability of genomic changes 
occurring in GC cells, from the first tumorigenic steps to 
the final acquisition of malignant and metastatic phenotype. 
For all these reasons, the treatment options are limited, 
and there is the urgent need to identify novel and specific 
markers for diagnosis, predictors of GC survival and overall 
new therapeutic strategies for treatment. 
H i g h - t h r o u g h p u t  a p p r o a c h e s  o f  e x o m e  a n d 
transcriptome wide analyses have identified new target 
genes potentially and, more importantly, consolidated the 
supremacy of known molecules already object of targeted 
therapies, identifying the key pathways commonly used by 
cancer cells to sustain oncogenic programs. The EGFR 
family provides oncogenic signals to epithelial cells by 
virtue of structural mutation, hyper-expression and gene 
amplification, facts that justify the continue effort to 
develop drugs, inhibitors and mAbs against these receptors, 
particularly ErbB2 and its downstream transducers. 
However, development of resistance to anti-ErbB2 mono-
therapies remains the major hurdle to overcome.
In principle, two can be the major mechanisms of 
resistance to anti ErbB2 therapy: an ex novo resistance, 
due to the occurrence of genetic alterations during tumor 
progression, occurring also in the ErbB2 signaling pathway; 
and acquired resistance, primarily due to the activation of 
alternative pathways to compensate for ErbB2 inhibition.
The network organization of the ErbB1-4 receptors 
appears to be ideally organized to supply mechanisms of 
escape from targeted-mono-therapies, due to their ability 
to aggregate in different dimer combination. This peculiar 
attitude confers robustness and redundancy to the signaling 
throughput, which is kept in shape even in relatively paucity 
of either one receptor. 
In cancer cells the administration of trastuzumab while 
disrupting the ErbB2 dimers, favors its aggregation with 
ErbB3. Heterodimers of ErbB2 and ErbB3 have been 
suggested to contain the highest growth and transforming 
potential of any dimer combination for the ability to recruit 
the largest set of agonistic signaling molecules, as compared 
to any other dimers containing ErbB2. This is more than 
hypothesis, and is actually one of the driving rationales 
for the “dual hit strategy” to combine pertuzumab and 
trastuzumab to efficiently target, no more the ErbB2 
receptor, but the dimers containing-ErbB2.
These observations highlight at least two other aspects 
that need to be considered: (I) the expression profile of the 
ErbB receptors, which is different for any given tumor; (II) 
the opportunity to target ErbB3, the preferred partner of 
ErbB2.
To the first aim, the molecular profiling of tumor cells 
to determine the relative levels of EGFR family members 
and their ligands, might be useful to predict sensitivity to 
trastuzumab or pertuzumab, and eventually decide which 
one to use first, if not the combination of the two. In fact, 
the sharp peculiar differences in the binding ability of these 
two mAbs to ErbB2 makes them precious tools that can be 
used in combination to control dimer formation. 
The ErbB3 receptor  i s  ac t ivated  in  a l los ter ic 
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conformation by its kinase active partner receptors, and 
works as a dynamic signaling hub linking their signals to 
the downstream PI3K/Akt signaling pathway. As such, 
the expression of ErbB3 is a potential point of impact 
in tumorigenic signaling and in drug resistance. These 
predictions have been validated in several experimental 
models. Although the proof of concept is not been achieved 
yet, the expectation arising from workbench and preclinical 
studies, for clinical relevant use of mAbs against ErbB3 in 
cancer therapy, alone or most likely in combination with 
anti-ErbB2 drugs, is high.
In principle, the best strategy to target a receptor devoid 
of intrinsic kinase activity like ErbB3 is to generate mAbs, 
and probably the best successful mAb would be able to 
promote receptor internalization and degradation (78,79). 
Its functions would have impact on signal attenuation 
of both PI3K and ERK pathways, and favor the ErbB2 
redistribution towards homodimers formation, leading 
to the possibility to target them with trastuzumab. 
However, a low percentage of tumors express mutations 
in the ErbB3 ECD able to activate its kinase in absence of 
heterodimerization, and for these, kinase inhibitors will be 
better drugs. 
In conclusion, although trastuzumab has been approved 
for treatment of ErbB2-positive GC, a significant 
proportion of patients did not respond or developed 
acquired resistance to this mAb (ToGA trial), indicating 
that an ErbB2 targeted mono-therapy can be elusive, 
leading to the activation of compensatory pathways in GC 
cells. Therefore, understanding mechanisms of resistance 
to ErbB2-target therapy is expected to identify criteria for 
choosing treatments, more rational and less empiric. Due to 
the complex regulation of the ErbB receptors composition 
occurring during prolonged targeted therapies, monitoring 
of the ErbB-related genetic feedbacks regulating receptor 
level expression and pathway activation may be strategic 
to control efficacy and toxicity of anticancer agents. 
Furthermore, the availability of therapeutic mAbs anti 
ErbB3 to synergistically block multiple ErbB receptor 
dimers will speed up knowledge on this field, opening a new 
frontier for the ErbB-targeted therapy of cancer. 
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